ID

31074

Descrizione

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE); ODM derived from: https://clinicaltrials.gov/show/NCT00719472

collegamento

https://clinicaltrials.gov/show/NCT00719472

Keywords

versioni (1)
  1. 18/07/18 18/07/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

18 luglio 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Non-Hodgkin's Lymphoma NCT00719472

Inglese

Eligibility Non-Hodgkin's Lymphoma NCT00719472

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
written informed consent
Descrizione

Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
age ≥ 18 years
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
patients with previously untreated diffuse large b-cell lymphoma (dlbcl) who are scheduled to receive rituximab 375 mg/m^2 plus chop (cyclophosphamide, hydroxydaunorubicin [also called doxorubicin or adriamycin], oncovin [vincristine], prednisone or prednisolone) chemotherapy, or previously untreated follicular non-hodgkin lymphoma (nhl) who are scheduled to receive rituximab 375 mg/m^2 plus cvp (cyclophosphamide, vincristine, prednisolone) chemotherapy
Descrizione

Diffuse Large B-Cell Lymphoma untreated | Rituximab plus CHOP Scheduled | Doxorubicin | Adriamycin | Oncovin | Vincristine | Prednisone | Prednisolone | Follicular Lymphoma untreated | Rituximab plus CVP Scheduled

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0079744
UMLS CUI [1,2]
C0332155
UMLS CUI [2,1]
C0393022
UMLS CUI [2,2]
C0332287
UMLS CUI [2,3]
C0163868
UMLS CUI [2,4]
C0205539
UMLS CUI [3]
C0013089
UMLS CUI [4]
C0085752
UMLS CUI [5]
C0591904
UMLS CUI [6]
C0042679
UMLS CUI [7]
C0032952
UMLS CUI [8]
C0032950
UMLS CUI [9,1]
C0024301
UMLS CUI [9,2]
C0332155
UMLS CUI [10,1]
C0393022
UMLS CUI [10,2]
C0332287
UMLS CUI [10,3]
C0056633
UMLS CUI [10,4]
C0205539
eastern cooperative oncology group (ecog) performance status 0-2
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
* clinically significant cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), new york heart association (nyha) classification grade ii or greater congestive heart failure, a ventricular arrhythmia requiring medication within 1 year prior to day 1, or nyha grade ii or greater peripheral vascular disease on day 1 (first day of treatment)
Descrizione

Cardiovascular Disease | Uncontrolled hypertension | Myocardial Infarction | Angina, Unstable | Congestive heart failure New York Heart Association Classification | Ventricular arrhythmia Requirement Pharmaceutical Preparations | Peripheral Vascular Disease New York Heart Association Classification

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2]
C1868885
UMLS CUI [3]
C0027051
UMLS CUI [4]
C0002965
UMLS CUI [5,1]
C0018802
UMLS CUI [5,2]
C1275491
UMLS CUI [6,1]
C0085612
UMLS CUI [6,2]
C1514873
UMLS CUI [6,3]
C0013227
UMLS CUI [7,1]
C0085096
UMLS CUI [7,2]
C1275491
patients who meet any of the following criteria will be excluded from further study participation after cycle 1:
Descrizione

Criteria Fulfill | Study Subject Participation Status Excluded

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
UMLS CUI [2,1]
C2348568
UMLS CUI [2,2]
C0332196
circulating lymphocyte count > 5,000/μl before the cycle 2 rituximab infusion
Descrizione

Circulating Lymphocyte Count

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0175630
UMLS CUI [1,2]
C0200635
development of a serious and/or grade 3 or 4 adverse event during cycle 1 judged by the investigator to be related to the rituximab infusion
Descrizione

Adverse event Serious | Adverse event CTCAE Grades | Relationship Rituximab Infusion

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0877248
UMLS CUI [1,2]
C0205404
UMLS CUI [2,1]
C0877248
UMLS CUI [2,2]
C1516728
UMLS CUI [3,1]
C0439849
UMLS CUI [3,2]
C0393022
UMLS CUI [3,3]
C0574032
prior premedication with additional corticosteroids other than the prednisone included in the chemotherapy regimens
Descrizione

Premedication Adrenal Cortex Hormones Additional | Exception Prednisone

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0033045
UMLS CUI [1,2]
C0001617
UMLS CUI [1,3]
C1524062
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0032952
Ritorna all'inizio della pagina

Similar models

Eligibility Non-Hodgkin's Lymphoma NCT00719472

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
age ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
Diffuse Large B-Cell Lymphoma untreated | Rituximab plus CHOP Scheduled | Doxorubicin | Adriamycin | Oncovin | Vincristine | Prednisone | Prednisolone | Follicular Lymphoma untreated | Rituximab plus CVP Scheduled
Item
patients with previously untreated diffuse large b-cell lymphoma (dlbcl) who are scheduled to receive rituximab 375 mg/m^2 plus chop (cyclophosphamide, hydroxydaunorubicin [also called doxorubicin or adriamycin], oncovin [vincristine], prednisone or prednisolone) chemotherapy, or previously untreated follicular non-hodgkin lymphoma (nhl) who are scheduled to receive rituximab 375 mg/m^2 plus cvp (cyclophosphamide, vincristine, prednisolone) chemotherapy
boolean
C0079744 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0393022 (UMLS CUI [2,1])
C0332287 (UMLS CUI [2,2])
C0163868 (UMLS CUI [2,3])
C0205539 (UMLS CUI [2,4])
C0013089 (UMLS CUI [3])
C0085752 (UMLS CUI [4])
C0591904 (UMLS CUI [5])
C0042679 (UMLS CUI [6])
C0032952 (UMLS CUI [7])
C0032950 (UMLS CUI [8])
C0024301 (UMLS CUI [9,1])
C0332155 (UMLS CUI [9,2])
C0393022 (UMLS CUI [10,1])
C0332287 (UMLS CUI [10,2])
C0056633 (UMLS CUI [10,3])
C0205539 (UMLS CUI [10,4])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Cardiovascular Disease | Uncontrolled hypertension | Myocardial Infarction | Angina, Unstable | Congestive heart failure New York Heart Association Classification | Ventricular arrhythmia Requirement Pharmaceutical Preparations | Peripheral Vascular Disease New York Heart Association Classification
Item
* clinically significant cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), new york heart association (nyha) classification grade ii or greater congestive heart failure, a ventricular arrhythmia requiring medication within 1 year prior to day 1, or nyha grade ii or greater peripheral vascular disease on day 1 (first day of treatment)
boolean
C0007222 (UMLS CUI [1])
C1868885 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0018802 (UMLS CUI [5,1])
C1275491 (UMLS CUI [5,2])
C0085612 (UMLS CUI [6,1])
C1514873 (UMLS CUI [6,2])
C0013227 (UMLS CUI [6,3])
C0085096 (UMLS CUI [7,1])
C1275491 (UMLS CUI [7,2])
Criteria Fulfill | Study Subject Participation Status Excluded
Item
patients who meet any of the following criteria will be excluded from further study participation after cycle 1:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
C2348568 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
Circulating Lymphocyte Count
Item
circulating lymphocyte count > 5,000/μl before the cycle 2 rituximab infusion
boolean
C0175630 (UMLS CUI [1,1])
C0200635 (UMLS CUI [1,2])
Adverse event Serious | Adverse event CTCAE Grades | Relationship Rituximab Infusion
Item
development of a serious and/or grade 3 or 4 adverse event during cycle 1 judged by the investigator to be related to the rituximab infusion
boolean
C0877248 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0877248 (UMLS CUI [2,1])
C1516728 (UMLS CUI [2,2])
C0439849 (UMLS CUI [3,1])
C0393022 (UMLS CUI [3,2])
C0574032 (UMLS CUI [3,3])
Premedication Adrenal Cortex Hormones Additional | Exception Prednisone
Item
prior premedication with additional corticosteroids other than the prednisone included in the chemotherapy regimens
boolean
C0033045 (UMLS CUI [1,1])
C0001617 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0032952 (UMLS CUI [2,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial